Previous 10 | Next 10 |
2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...
2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....
2023-05-12 11:50:49 ET Heron Therapeutics ( NASDAQ: HRTX ) stock fell ~35% on Friday after Q1 2023 results missed estimates. Its Q1 net loss narrowed to -$32.77M, compared to -63.89M in Q1 2022. Net product sales grew 26.2% Y/Y to $29.62M but missed analysts expectat...
2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...
2023-05-11 22:18:06 ET Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Craig Collard - Chief Executive Officer David Szekeres - Executive Vice President & Chief Operating Officer Conference Call...
2023-05-11 16:03:42 ET Heron Therapeutics press release ( NASDAQ: HRTX ): Q1 GAAP EPS of -$0.27 misses by $0.07 . Revenue of $29.62M (+26.3% Y/Y) misses by $0.07M . For further details see: Heron Therapeutics GAAP EPS of -$0.27 misses by $0.07, revenue of...
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates PR Newswire · Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million , Compared to First Quarter Net Product Sales in 2022 ...
2023-05-10 17:35:58 ET Heron Therapeutics ( NASDAQ: HRTX ) is scheduled to announce Q1 earnings results on Thursday, May 11th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $29.69M (+26.6% Y/Y). Over the last 1 year, HRT...
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 PR Newswire SAN DIEGO , May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of pat...
2023-04-26 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...